Changes at the top within Recordati. Following the farewell of Alfredo Altavilla, who will become president of Italy, the new airline that will take the place of Alitalia, the pharmaceutical group reorganizes its Governance. Rob Koremans will be the new CEO, while Andrea Recordati, the company's current CEO, will take on the role of president. The new positions will become operational from 1 December 2021.
Koremans, a medical graduate from RSM Erasmus University in the Netherlands, has over 30 years of experience in managerial and executive roles, mainly gained in the pharmaceutical industry at various international companies, including Serono, Grunenthal, Sanofi-Aventis and Teva. In 2018, he was appointed CEO of Nutreco, a global animal nutrition company. Previously, he was president and CEO of Global Specialty Medicines and a member of the Executive Committee of Teva Pharmaceutical Industries Ltd.
Under the leadership of Rob Koremans, Recordati will continue to consolidate its trajectory, as defined in the recent three-year plan, combining the organic growth in volumes of the current portfolio with the creation of value through Business Development and M&A operations, the company confirmed in a note. As future president, Andrea Recordati will continue to participate in the elaboration of the group's strategy, in support of the new CEO and the senior management team.
“We have worked in recent years to strengthen our management team and I think now is the right time to bring in a CEO of Rob's caliber. I will transition into the role of President, ensuring continuity and will work closely with Rob to support a smooth transition and execution of corporate strategy. I would also like to thank Alfredo for his excellent contribution to the Group and the board during his tenure as chairman,” he said Andrea Recordati.
“I am thrilled to join Recordati and continue to lead it towards sustainable growth, helping people living with a variety of diseases address the healthcare challenges they are experiencing. Recordati has a history full of successes. Under Andrea's leadership, the company has continued to achieve excellent results over the years even after the change of ownership, positioning itself as a unique platform for growth. My commitment will be to pursue all opportunities for patients and all stakeholders, to continue the success of Recordati", declared Rob Koremans.
“I am very pleased to have successfully contributed to the evolution of Recordati towards an institutional governance model, as agreed with the controlling shareholder at the time of my appointment as chairman”, added the outgoing chairman, Alfredo Altavilla.
After the announcement of the new top management, in Piazza Affari the Recordati title started trading down by 0,4% before moving above parity (+0,2%) by mid-morning.
